China’s Bitter Medicine for Gilead: SIPO Cancels Viread Patent
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This landmark ruling comes on the heels of recent changes to China’s compulsory licensing scheme for pharmaceutical products. This quick-step of legislative reform followed by the […]